These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38616241)

  • 1. Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.
    Oldenburg J; Chambost H; Liu H; Hawes C; You X; Yang X; Newman V; Robinson TM; Hatswell AJ; Hinds D; Santos S; Ozelo M
    Adv Ther; 2024 Jun; 41(6):2267-2281. PubMed ID: 38616241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
    Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
    Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
    Mahlangu J; Kaczmarek R; von Drygalski A; Shapiro S; Chou SC; Ozelo MC; Kenet G; Peyvandi F; Wang M; Madan B; Key NS; Laffan M; Dunn AL; Mason J; Quon DV; Symington E; Leavitt AD; Oldenburg J; Chambost H; Reding MT; Jayaram K; Yu H; Mahajan R; Chavele KM; Reddy DB; Henshaw J; Robinson TM; Wong WY; Pipe SW;
    N Engl J Med; 2023 Feb; 388(8):694-705. PubMed ID: 36812433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
    Ozelo MC; Mahlangu J; Pasi KJ; Giermasz A; Leavitt AD; Laffan M; Symington E; Quon DV; Wang JD; Peerlinck K; Pipe SW; Madan B; Key NS; Pierce GF; O'Mahony B; Kaczmarek R; Henshaw J; Lawal A; Jayaram K; Huang M; Yang X; Wong WY; Kim B;
    N Engl J Med; 2022 Mar; 386(11):1013-1025. PubMed ID: 35294811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A.
    Agarwal S; Hermans C; Miesbach W; Peyvandi F; Sidonio R; Osmond D; Newman V; Henshaw J; Pipe S
    Haemophilia; 2024 Jul; 30(4):905-913. PubMed ID: 38684460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.
    Madan B; Ozelo MC; Raheja P; Symington E; Quon DV; Leavitt AD; Pipe SW; Lowe G; Kenet G; Reding MT; Mason J; Wang M; von Drygalski A; Klamroth R; Shapiro S; Chambost H; Dunn AL; Oldenburg J; Chou SC; Peyvandi F; Millar CM; Osmond D; Yu H; Dashiell-Aje E; Robinson TM; Mahlangu J
    J Thromb Haemost; 2024 Jul; 22(7):1880-1893. PubMed ID: 38614387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A.
    Cook K; Forbes SP; Adamski K; Ma JJ; Chawla A; Garrison LP
    J Med Econ; 2020 May; 23(5):501-512. PubMed ID: 31971453
    [No Abstract]   [Full Text] [Related]  

  • 8. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.
    Pasi KJ; Laffan M; Rangarajan S; Robinson TM; Mitchell N; Lester W; Symington E; Madan B; Yang X; Kim B; Pierce GF; Wong WY
    Haemophilia; 2021 Nov; 27(6):947-956. PubMed ID: 34378280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A.
    Long BR; Robinson TM; Day JRS; Yu H; Lau K; Imtiaz U; Patton KS; de Hart G; Henshaw J; Agarwal S; Vettermann C; Zoog SJ; Gupta S
    Mol Ther; 2024 Jul; 32(7):2052-2063. PubMed ID: 38796703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1.
    O'Mahony B; Dunn AL; Leavitt AD; Peyvandi F; Ozelo MC; Mahlangu J; Peerlinck K; Wang JD; Lowe GC; Tan CW; Giermasz A; Tran H; Khoo TL; Cockrell E; Pepperell D; Chambost H; López Fernández MF; Kazmi R; Majerus E; Skinner MW; Klamroth R; Quinn J; Yu H; Wong WY; Robinson TM; Pipe SW
    J Thromb Haemost; 2023 Dec; 21(12):3450-3462. PubMed ID: 37678546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment.
    Symington E; Rangarajan S; Lester W; Madan B; Pierce GF; Raheja P; Robinson TM; Osmond D; Russell CB; Vettermann C; Agarwal SK; Li M; Wong WY; Laffan M
    Haemophilia; 2024 Mar; 30(2):320-330. PubMed ID: 38317480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B.
    Dougherty JA; Dougherty KM
    Ann Pharmacother; 2024 Aug; 58(8):834-848. PubMed ID: 37978816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
    Olasupo OO; Noronha N; Lowe MS; Ansel D; Bhatt M; Matino D
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD014544. PubMed ID: 38411279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A.
    Symington E; Rangarajan S; Lester W; Madan B; Pierce GF; Raheja P; Millar C; Osmond D; Li M; Robinson TM
    Haemophilia; 2024 Jul; ():. PubMed ID: 38975624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twice Weekly Vs. Thrice Weekly Low-Dose Prophylactic Factor VIII Therapy in Children with Hemophilia A: An Open Label Randomized Trial.
    Gomber S; Singhal G; Dewan P; Upreti L; Sikka M
    J Trop Pediatr; 2022 Apr; 68(3):. PubMed ID: 35595254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting.
    Ay C; Perschy L; Rejtö J; Kaider A; Pabinger I
    Ann Hematol; 2020 Dec; 99(12):2763-2771. PubMed ID: 32918114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valoctocogene Roxaparvovec: First Approval.
    Blair HA
    Drugs; 2022 Sep; 82(14):1505-1510. PubMed ID: 36214970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
    Reding MT; Ng HJ; Poulsen LH; Eyster ME; Pabinger I; Shin HJ; Walsch R; Lederman M; Wang M; Hardtke M; Michaels LA
    J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.